dc.contributor.author |
Berber, Ilhami |
|
dc.contributor.author |
Erkurt, Mehmet Ali |
|
dc.contributor.author |
Tuglular, Tulin Firatli |
|
dc.date.accessioned |
2019-10-04T06:48:38Z |
|
dc.date.available |
2019-10-04T06:48:38Z |
|
dc.date.issued |
2016 |
|
dc.identifier.citation |
Berber, I. Erkurt, MA. Tuglular, TF. (2016). The Role of Azacitidine in the Treatment of Elderly Patients with Acute Myeloid Leukemia: Results of a Retrospective Multicenter Study. Cilt:33. Sayı:4. 273-280 ss. |
tr_TR |
dc.identifier.uri |
http://hdl.handle.net/11616/14490 |
|
dc.description.abstract |
Objective: In this study, we aimed to investigate the efficacy and safety of azacitidine (AZA) in elderly patients with acute myeloid leukemia (AML), including patients with >30% bone marrow (BM) blasts.
Materials and Methods: In this retrospective multicenter study, 130 patients of >= 60 years old who were ineligible for intensive chemotherapy or had progressed despite conventional treatment were included.
Results: The median age was 73 years and 61.5% of patients had >30% BM blasts. Patients received AZA for a median of four cycles (range: 1-21). Initial overall response [including complete remission (CR)/CR with incomplete recovery/partial remission] was 36.2%. Hematologic improvement (HI) of any kind was documented in 37.7% of all patients. HI was also documented in 27.1% of patients who were unresponsive to treatment. Median overall survival (OS) was 18 months for responders and 12 months for nonresponders (p=0.005). In the unresponsive patient group, any HI improved OS compared to patients without any HI (median OS was 14 months versus 10 months, p=0.068). Eastern Cooperative Oncology Group performance status of <2, increasing number of AZA cycles (>= 5 courses), and any HI predicted better OS. Age, AML type, and BM blast percentage had no impact.
Conclusion: We conclude that AZA is effective and well tolerated in elderly comorbid AML patients, irrespective of BM blast count, and HI should be considered a sufficient response to continue treatment with AZA. |
tr_TR |
dc.language.iso |
eng |
tr_TR |
dc.publisher |
Galenos yayıncılık, erkan mor, molla guranı cad 21-1, fındıkzade, ıstanbul 34093, turkey |
tr_TR |
dc.relation.isversionof |
10.4274/tjh.2015.0203 |
tr_TR |
dc.rights |
info:eu-repo/semantics/restrictedAccess |
tr_TR |
dc.subject |
Conventıonal care regımens |
tr_TR |
dc.subject |
rısk myelodysplastıc syndrome |
tr_TR |
dc.subject |
ınternatıonal workıng group |
tr_TR |
dc.subject |
acute myelogenous leukemıa |
tr_TR |
dc.subject |
newly-dıagnosed aml |
tr_TR |
dc.subject |
older patıents |
tr_TR |
dc.subject |
ıntensıve chemotherapy |
tr_TR |
dc.subject |
response crıterıa |
tr_TR |
dc.subject |
age |
tr_TR |
dc.subject |
cytarabıne |
tr_TR |
dc.title |
The Role of Azacitidine in the Treatment of Elderly Patients with Acute Myeloid Leukemia: Results of a Retrospective Multicenter Study |
tr_TR |
dc.type |
article |
tr_TR |
dc.relation.ispartof |
Turkısh journal of hematology |
tr_TR |
dc.department |
İnönü Üniversitesi |
tr_TR |
dc.identifier.volume |
33 |
tr_TR |
dc.identifier.issue |
4 |
tr_TR |
dc.identifier.startpage |
273 |
tr_TR |
dc.identifier.endpage |
280 |
tr_TR |